Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Department of Defense (DOD) Traumatic Brain Injury & Psychological Health Research Program (TBIPHRP)

Research Admin Offices:

  • HRS

Funding Type:

Grant

Opportunity Type:

  • Grant

Value:

Clinical Trial Award (CTA)

  • Research Level 1
    • Maximum funding of $500,000 for direct costs (plus indirect costs) 6
    • Maximum period of performance is 3years
  • Research Level 2
    • Maximum funding of $2,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 4years
  • Research Level 3
    • Maximum funding of $4,000,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 4years

Focused Program Award (FPA)

  • Maximum funding of $5,000,000 for direct costs (plus indirect costs)

Investigator Initiated Research Award (IIRA)

  • Maximum funding of $500,000 for direct costs (plus indirect costs)

Translational Research Award (TRA)

  • Maximum funding of $1,000,000 for direct costs (plus indirect costs).

Patient-Centred Research Award (PCRA)

  • Maximum funding of $1,000,000 for direct costs (plus indirect costs).

Disciplines:

  • Health Sciences

Sponsors:

Deadlines:

Internal Deadline:

August 18, 2022

Sponsor Deadline:

December 8, 2022

Description:

The current Peer-Reviewed Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) complements ongoing DOD efforts toward promoting a better standard of care for psychological health and traumatic brain injury in the areas of prevention, detection, diagnosis, treatment, and rehabilitation. To efficiently manage the TBIPHRP, CDMRP will utilize its two tiered review process.

Clinical Trial Award (CTA)

  • Supports the rapid implementation of clinical trials with the potential to have a significant impact on psychological health and/or TBI through clinical applications, including healthcare products, technologies, and/or practice guidelines.
  • Submissions of preproposal is required; application submission is by invitation only.
  • Different Research Levels, based on the scope of research, are available. It is the responsibility of the Principal Investigator (PI) to select the Research Level that is most appropriate for the research proposed.
  • The following are general descriptions, although not all-inclusive, of the scope of the research projects that would be appropriate to propose under each Research Level:
    • Research Level 1: Proof-of-principle pilot trials, correlative studies, and other innovative, exploratory clinical trials.
      • Early-Career Partnering Investigator Option is available
    • Research Level 2: Clinical trials for promising treatments or interventions that have already demonstrated acceptable safety in human subjects.
    • Research Level 3: Large-scale clinical trials to demonstrate efficacy in relevant patient populations.

Focused Program Award (FPA)

  • Supports a synergistic, multidisciplinary research program of at least four distinct but complimentary projects addressing an overarching goal.
  • Individual projects must be capable of standing on their own high scientific merits, they must also be interrelated, synergistic, and align with the overarching challenge to advance a solution beyond what would be possible through individual efforts.
  • Individual research projects may include applied research, preclinical research, clinical research and clinical trials.
  • Proposed research projects should not include basic research. Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
  • Submission of a preproposal is required; application submission is by invitation only.

Investigator Initiated Research Award (IIRA)

  • Supports research that will make an important contribution toward understanding, preventing, assessing, and treating psychological health and/or TBI conditions.
  • Early-Career Partnering PI Option is available.
  • Clinical trials will not be supported.
  • Submission of a Letter of Intent is required prior to full application submission.

Translational Research Award (TRA)

  • Supports the translation of promising research into clinical application (i.e., preclinical to clinical translation).
  • May support small-scale pilot clinical trial when necessary to inform the next step in clinical development.
  • Partnering PI Option is available.
  • Submission of a Letter of Intent is required prior to full application submission.

Patient-Centred Research Award (PCRA)

  • Supports research to bridge the gap between research, practice, and policy by building a knowledge base on how interventions and clinical practices/guidelines and policies can be deployed to targeted populations at the appropriate time at the point of need.
  • Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research.
  • The application must include Community Based Participatory Research (CBPR) approaches in the development and execution of the clinical research/trial.
  • FY22 PCRA may support (not all inclusive):
    • Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat and monitor health conditions in “real world” settings.
    • Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines.
    • Analysis of existing data or resources to inform clinical practice.
    • Modification of established clinical tools for their intended population or environment.
    • Analysis of existing clinical tools to maximize patient-relevant outcomes.
    • Identification and analysis of the circumstances that create a need to stop or reduce (“de-implement”) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful is within scope.
  • Submission of a Letter of Intent is required prior to full application submission.

Additional Program Information:

Clinical Trial Award (CTA)

Internal Pre-Application Deadline: August 18, 2022
Pre-Application Deadline: September 1, 2022 by 5:00 p.m. (ET)
Internal Full Application Deadline: November 24, 2022*
Sponsor Full Application Deadline: December 8, 2022 by 11:59 p.m. (ET)*
*By invitation only

Focused Program Award (FPA)

Internal Pre-Application Deadline: August 18, 2022
Pre-Application Deadline: September 1, 2022 by 5:00 p.m. (ET)
Internal Full Application Deadline: November 24, 2022*
Sponsor Full Application Deadline: December 8, 2022 by 11:59 p.m. (ET)*
*By invitation only

Investigator Initiated Research Award (IIRA)

Internal Pre-Application (LOI) Deadline: August 10, 2022
Pre-Application (LOI) Deadline: August 24, 2022 by 5:00 p.m. (ET)
Internal Full Application Deadline: August 31, 2022
Sponsor Full Application Deadline: September 14, 2022 by 11:59 p.m. (ET)

Translational Research Award (TRA)

Internal Pre-Application (LOI) Deadline: August 10, 2022
Pre-Application (LOI) Deadline: August 24, 2022 by 5:00 p.m. (ET)
Internal Full Application Deadline: August 31, 2022
Sponsor Full Application Deadline: September 14, 2022 by 11:59 p.m. (ET)

Patient-Centred Research Award (PCRA)

Internal Pre-Application (LOI) Deadline: August 10, 2022
Pre-Application (LOI) Deadline: August 24, 2022 by 5:00 p.m. (ET)
Internal Full Application Deadline: August 31, 2022
Sponsor Full Application Deadline: September 14, 2022 by 11:59 p.m. (ET)

Eligibility:

Clinical Trial Award (CTA)

  • Extramural applicants only.
    • Investigators at the level of Assistant Professor and above (or equivalent) Early-Career Investigator Partnering Option:
    • An independent, early-career investigator within 10 years after completion of terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave).

Focused Program Award (FPA)

  • Extramural applicants only.
  • Investigators at the level of Assistant Professor and above (or equivalent).

Investigator Initiated Research Award (IIRA)

  • Extramural applicants only
  • Investigators at the level of Assistant Professor and above (or equivalent).
  • Early-Career Investigator Partnering Option: An independent, early-career investigator within 10 years after completion of terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave).

Translational Research Award (TRA)

  • Investigators at the level of Assistant Professor and above (or equivalent)

Patient-Centred Research Award (PCRA)

  • Investigators at the level of Assistant Professor and above (or equivalent).

Application/Nomination Process:

  • Submission is a two-step process requiring both pre-application and full application.
  • All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance.
  • Peer Review: December 2022.
  • Programmatic Review: March 2023.

Resources:

Additional Details

Contact:

If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.